SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

Multiple myeloma (MM)-associated osteolytic bone disease is a major cause of morbidity and mortality in MM patients and the development of new therapeutic strategies is of great interest. The proto-oncogene SRC is an attractive target for such a strategy. In the current study, we investigated the ef...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Heusschen, Roy, Muller, Joséphine, Binsfeld, Marilène, Marty, Caroline, Plougonven, Erwan, Dubois, Sophie, Mahli, Nadia, Moermans, Karen, Carmeliet, Geert, Léonard, Angélique, Baron, Frédéric, Beguin, Yves, Menu, Eline, Cohen-Solal, Martine, Caers, Jo
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5058712/
https://ncbi.nlm.nih.gov/pubmed/27095574
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8750
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi